WO2002064167A3 - Agents actifs au niveau biologique - Google Patents
Agents actifs au niveau biologique Download PDFInfo
- Publication number
- WO2002064167A3 WO2002064167A3 PCT/GB2002/000575 GB0200575W WO02064167A3 WO 2002064167 A3 WO2002064167 A3 WO 2002064167A3 GB 0200575 W GB0200575 W GB 0200575W WO 02064167 A3 WO02064167 A3 WO 02064167A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostaglandin
- proteinaceous
- agent
- complex
- biologically active
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 4
- 230000005070 ripening Effects 0.000 abstract 3
- 210000001616 monocyte Anatomy 0.000 abstract 2
- 210000000440 neutrophil Anatomy 0.000 abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 210000003679 cervix uteri Anatomy 0.000 abstract 1
- 230000003399 chemotactic effect Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un complexe comprenant un agent protéique qui est chimiotactique pour des monocytes et/ou des neutrophiles, et une prostaglandine. L'invention concerne également un procédé de fabrication d'un complexe comprenant un agent protéique qui est chimiotactique pour des monocytes et/ou des neutrophiles, et une prostaglandine. Ce procédé comprend l'étape consistant à mélanger l'agent protéique de maturation du col et la prostaglandine dans des conditions dans lesquelles ils entrent en contact intime. De préférence, l'agent protéique de maturation du col est MCP-1 ou IL-8 ou un dérivé de ceux-ci. De préférence, la prostaglandine est PGE2. Ce complexe ou des compositions pharmaceutiques de celui-ci sont utiles pour la maturation du col utérin chez une femme qui en a besoin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0103354.7 | 2001-02-10 | ||
| GBGB0103354.7A GB0103354D0 (en) | 2001-02-10 | 2001-02-10 | Biologically active agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002064167A2 WO2002064167A2 (fr) | 2002-08-22 |
| WO2002064167A3 true WO2002064167A3 (fr) | 2003-04-17 |
Family
ID=9908517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2002/000575 WO2002064167A2 (fr) | 2001-02-10 | 2002-02-11 | Agents actifs au niveau biologique |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0103354D0 (fr) |
| WO (1) | WO2002064167A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972957A1 (fr) | 2015-01-05 | 2016-07-14 | Cornell University | Compositions et procedes utilisant de l'il-8 pour ameliorer la production de lait et la sante reproductive chez les mammiferes |
| US11464831B2 (en) | 2015-01-05 | 2022-10-11 | Cornell University | Compositions and methods using IL-8 for improving health of mammals |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008777A1 (fr) * | 1989-01-31 | 1990-08-09 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | PRODUIT PROTEIQUE PURIFIE D'ORIGINE HUMAINE A ATTRACTION MONOCYTAIRE, UTILE DANS UN PROCEDE DE TRAITEMENT D'AFFECTIONS ET DE NEOPLASMES DANS LE CORPS HUMAIN, ET CLONAGE DE SON ADNc DE LONGUEUR NORMALE |
| US5624670A (en) * | 1991-11-21 | 1997-04-29 | Medical Research Council | Use of interleukin-8 for inducing cervical ripening |
| US5908829A (en) * | 1994-03-31 | 1999-06-01 | Medical Research Council | Use of MCP-1 for inducing ripening of the cervix |
-
2001
- 2001-02-10 GB GBGB0103354.7A patent/GB0103354D0/en not_active Ceased
-
2002
- 2002-02-11 WO PCT/GB2002/000575 patent/WO2002064167A2/fr not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008777A1 (fr) * | 1989-01-31 | 1990-08-09 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | PRODUIT PROTEIQUE PURIFIE D'ORIGINE HUMAINE A ATTRACTION MONOCYTAIRE, UTILE DANS UN PROCEDE DE TRAITEMENT D'AFFECTIONS ET DE NEOPLASMES DANS LE CORPS HUMAIN, ET CLONAGE DE SON ADNc DE LONGUEUR NORMALE |
| US5624670A (en) * | 1991-11-21 | 1997-04-29 | Medical Research Council | Use of interleukin-8 for inducing cervical ripening |
| US5908829A (en) * | 1994-03-31 | 1999-06-01 | Medical Research Council | Use of MCP-1 for inducing ripening of the cervix |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0103354D0 (en) | 2001-03-28 |
| WO2002064167A2 (fr) | 2002-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2298812A3 (fr) | Remèdes pour maladies associées à l'arthrite chronique chez l'enfant | |
| MY162623A (en) | Immunoglobulin formulation and method of preparation thereof | |
| WO2003044076A8 (fr) | Poly(ortho esters) bioerodables comprenant des groupes amines, et copolymeres en bloc les contenant | |
| HK1067544A1 (en) | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms | |
| WO2002056900A3 (fr) | Utilisation de slpi pour traiter des maladies intestinales inflammatoires chroniques | |
| NO20040564L (no) | Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel | |
| ATE373464T1 (de) | Bioadhäsive terapeutische systeme mit verzögerter freisetzung | |
| CA2396159A1 (fr) | Nouvelles formes posologiques de benzimidazole substitue | |
| HK1066468A1 (en) | Aqueous sustained-release formulations of proteins | |
| WO2002055098A3 (fr) | Methode pour conferer un temps de latence a des substances pharmaceutiquement actives | |
| AU2002335815A1 (en) | High-concentration protein formulations and method of manufacture | |
| DE50105771D1 (de) | Ibuprofen-wirkstoffzubereitung | |
| ITRM20010476A0 (it) | Lamine di epitelio corneale umano ricostruite e metodo per il loro ottenimento. | |
| AU2001267886A1 (en) | Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them | |
| WO2003020200A3 (fr) | Nouveau compose pharmaceutique et procedes de fabrication et d'utilisation de ce compose | |
| WO2002064167A3 (fr) | Agents actifs au niveau biologique | |
| RS20050662A (en) | Liquid formulations of tumor necrosis factor-binding proteins | |
| BRPI0413446A (pt) | gel bioadesivo á base de hidroxietilcelulose | |
| AU2002341555A1 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
| AU8799001A (en) | Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases | |
| MY130445A (en) | Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone | |
| ITRM20010048A0 (it) | Metodo per preparare soluzioni acquose fisiologicamente accettabili esoluzioni cosi' ottenute. | |
| WO2003026621A3 (fr) | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu | |
| WO2004035023A8 (fr) | Utilisation d'elements moules pour une application externe | |
| WO2004058999A3 (fr) | Procede et dispositif de determination de certains etats ou changements de l'epithelium uterin et de l'epithelium d'autres organes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |